Melanoma Molecular Maps Projects


Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;

  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);

  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.

Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.

The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.


"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

Altered integrin expression patterns shown by microarray in human cutaneous melanoma.
Vizkeleti L, Kiss T, Koroknai V, Ecsedi S, Papp O, Szasz I, Adany R, Balazs M
Melanoma Res. 2017 Feb 23;():.
PMID: 28234767 [PubMed - as supplied by publisher]

The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.
Jones MS, Jones PC, Stern SL, Elashoff D, Hoon DS, Thompson J, Mozzillo N, Nieweg OE, Noyes D, Hoekstra HJ, Zager JS, Roses DF, Testori A, Coventry BJ, Smithers MB, Andtbacka R, Agnese D, Schultz E, Hsueh EC, Kelley M, Schneebaum S, Jacobs L, Bowles T, Kashani-Sabet M, Johnson D, Faries MB
Ann Surg Oncol. 2017 Feb 21;():.
PMID: 28224364 [PubMed - as supplied by publisher]

Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
Babapoor S, Wu R, Kozubek J, Auidi D, Grant-Kels JM, Dadras SS
Lab Invest. 2017 Feb 20;():.
PMID: 28218741 [PubMed - as supplied by publisher]

Glycaemic index, glycaemic load and risk of cutaneous melanoma in a population-based, case-control study.
Malavolti M, Malagoli C, Crespi CM, Brighenti F, Agnoli C, Sieri S, Krogh V, Fiorentini C, Farnetani F, Longo C, Ricci C, Albertini G, Lanzoni A, Veneziano L, Virgili A, Pagliarello C, Feliciani C, Fanti PA, Dika E, Pellacani G, Vinceti M
Br J Nutr. 2017 Feb 15;():1-7.
PMID: 28196548 [PubMed - as supplied by publisher]

Staging and follow-up of cutaneous melanoma patients.
Gutiérrez García-Rodrigo C, Antonini A, Rocco T, Pellegrini C, Fargnoli MC
G Ital Dermatol Venereol. 2017 Feb 14;():.
PMID: 28195451 [PubMed - as supplied by publisher]

NCBI's Disclaimer and Copyright notice